Please ensure Javascript is enabled for purposes of website accessibility

Opko Health Buys Prolor Biotech

By Rich Duprey - Apr 24, 2013 at 5:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

$480 million transaction will give biotech four products in late-stage trials.

In keeping with its objective to broaden its portfolio of market-transforming therapies in selected specialty markets, Opko Health (OPK 4.58%) has acquired Prolor Biotech (NYSEMKT: PBTH) in an all-stock deal.

Based on Opko's $7.03 share price at the time of the acquisition, the value of the deal is $480 million, and Opko will pay $7.00 per share for Prolor's stock. The deal is expected to close in the second half of 2013, subject to certain conditions including the approval of stockholders of both companies and other customary closing conditions.

Prolor's long-acting version of human growth hormone hGH-CTP has successfully completed four clinical trials, including a phase 2 trial in adults with growth hormone deficiency. hGH-CTP has been awarded orphan drug designation in the U.S. and Europe for both adults and children with GHD. A phase 2 trial in children with GHD is currently ongoing, and a phase 3 trial in adults with GHD is planned to begin in the second quarter of 2013.

Opko Health Chairman and CEO Dr. Phillip Frost said: "With the inclusion of Prolor's pipeline, Opko will have four significant products in Phase III clinical development and a robust pipeline of important therapeutic and unique diagnostic products in various stages of development. Prolor's drug-product candidates for growth hormone deficiency, hemophilia, obesity, and diabetes, along with its broadly applicable technology platforms and efficient research and development center, are highly valuable assets that will complement Opko's strategy."

Opko is a multinational biopharmaceutical and diagnostics company specializing in leveraging its discovery, development, and commercialization expertise in novel and proprietary technologies.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$3.20 (4.58%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.